Brendan M. Johnson
GlaxoSmithKline
9 Papers
64 Citations
Brendan M. Johnson is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Pharmacokinetics & Ondansetron. The author has an hindex of 7, co-authored 9 publications.
Chat about Author
Papers
Phase II Study to Evaluate the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist Casopitant (GW679769) Administered with Ondansetron for the Prevention of Postoperative and Postdischarge Nausea and Vomiting in High-risk Patients
Neil Singla,Sonia Singla,Frances Chung,Demetrios J. Kutsogiannis,Linda M. Blackburn,Stephen R. Lane,Jeremey Levin,Brendan M. Johnson,Joseph V. Pergolizzi +8 more
TL;DR: Compared with ondansetron alone, the casopitant and ondANSetron combination results in superior emesis prevention during the first 24 h postoperatively in female patients with known risk factors for postoperative nausea and vomiting.
A Phase 1 Trial of Eltrombopag in Patients Undergoing Stem Cell Transplantation after Total Body Irradiation
Jane L. Liesveld,Gordon L. Phillips,Michael Becker,Louis S. Constine,Jonathan W. Friedberg,Jeffrey R. Andolina,Laurie A. Milner,Jessica DeBolt,T. Smudzin,Ollivier Hyrien,Connie L. Erickson-Miller,Brendan M. Johnson,Katie-Louise Dawson,Yuhchyau Chen +13 more
TL;DR: It is concluded that up to 27 days of once-daily dosing of eltrombopag after stem cell transplantation is well tolerated, and no dose-limiting toxicities were observed in this heterogeneous post-transplantation patient population.
33
Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1−48 months
John T. Mondick,Brendan M. Johnson,Lynda J. Haberer,Mark E. Sale,Peter C. Adamson,Charles J. Coté,James M. Croop,Mark W. Russo,Jeffrey S. Barrett,J. Frank Hoke +9 more
TL;DR: The population pharmacokinetic analysis of ondansetron allows for characterization of individual patients based on body weight and age, and it is recommended that patients younger than 4 months receiving oncology and surgical patients aged 1–48 months be closely monitored.
21
Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia
Siobhan Hayes,Paul N. Mudd,Daniele Ouellet,Brendan M. Johnson,Daphne Williams,Daphne Williams,Ekaterina Gibiansky +6 more
TL;DR: Simulations indicated that eltrombopag administered 5 days before and 5 days after chemotherapy minimizes the decrease and fluctuations in platelet counts relative to other evaluated dosing regimens.
20
Development of Drug Substances as Mixture of Polymorphs: Studies to Control Form 3 in Casopitant Mesylate
Zadeo Cimarosti,Carlo Castagnoli,Marco Rossetti,Mirka Scarati,Caroline J. Day,Brendan M. Johnson,Pieter Westerduin +6 more
TL;DR: Polymorphism is characterized as the ability of a drug substance to exist as two or more crystalline phases that have different arrangements and/or conformations of the molecules in the crystal lattice as discussed by the authors.
19